Green Cross Holdings Past Earnings Performance
Past criteria checks 0/6
Green Cross Holdings's earnings have been declining at an average annual rate of -50.5%, while the Biotechs industry saw earnings growing at 1.6% annually. Revenues have been growing at an average rate of 7.9% per year.
Key information
-50.5%
Earnings growth rate
-50.5%
EPS growth rate
Biotechs Industry Growth | 11.7% |
Revenue growth rate | 7.9% |
Return on equity | -6.1% |
Net Margin | -3.6% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Is Green Cross Holdings (KRX:005250) Using Debt Sensibly?
Aug 09Know This Before Buying Green Cross Holdings Corporation (KRX:005250) For Its Dividend
Apr 28Is Now The Time To Put Green Cross Holdings (KRX:005250) On Your Watchlist?
Mar 21Green Cross Holdings (KRX:005250) Seems To Be Using A Lot Of Debt
Mar 01If You Had Bought Green Cross Holdings (KRX:005250) Stock A Year Ago, You Could Pocket A 106% Gain Today
Feb 12Here's What Green Cross Holdings Corporation's (KRX:005250) Shareholder Ownership Structure Looks Like
Jan 28We're Not So Sure You Should Rely on Green Cross Holdings's (KRX:005250) Statutory Earnings
Jan 12Green Cross Holdings Corporation (KRX:005250) Investors Should Think About This Before Buying It For Its Dividend
Dec 28Green Cross Holdings Corporation's (KRX:005250) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Dec 13Green Cross Holdings (KRX:005250) Use Of Debt Could Be Considered Risky
Nov 28Optimistic Investors Push Green Cross Holdings Corporation (KRX:005250) Shares Up 63% But Growth Is Lacking
Nov 28Revenue & Expenses Breakdown
How Green Cross Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 2,113,064 | -75,257 | 428,947 | 162,912 |
31 Mar 24 | 2,089,633 | -68,156 | 426,954 | 168,083 |
31 Dec 23 | 2,057,936 | -53,448 | 419,632 | 179,470 |
30 Sep 23 | 2,022,765 | -4,467 | 426,537 | 196,019 |
30 Jun 23 | 2,034,738 | 6,689 | 418,055 | 204,932 |
31 Mar 23 | 2,015,489 | 9,763 | 416,239 | 208,850 |
31 Dec 22 | 2,079,560 | 33,457 | 408,479 | 193,945 |
30 Sep 22 | 2,080,210 | 14,585 | 401,716 | 184,627 |
30 Jun 22 | 2,057,372 | 32,002 | 395,429 | 177,894 |
31 Mar 22 | 1,997,197 | 39,712 | 388,835 | 154,316 |
31 Dec 21 | 1,840,559 | 54,901 | 376,468 | 147,282 |
30 Sep 21 | 1,839,742 | 9,620 | 361,495 | 147,785 |
30 Jun 21 | 1,775,100 | 29,238 | 347,233 | 135,340 |
31 Mar 21 | 1,722,665 | 65,565 | 319,163 | 141,602 |
31 Dec 20 | 1,719,326 | 60,806 | 301,464 | 143,311 |
30 Sep 20 | 1,612,253 | 96,771 | 270,036 | 128,912 |
30 Jun 20 | 1,540,220 | 72,006 | 251,017 | 127,916 |
31 Mar 20 | 1,488,624 | 48,269 | 225,374 | 127,162 |
31 Dec 19 | 1,493,589 | 42,741 | 221,067 | 126,347 |
30 Sep 19 | 1,492,852 | 29,228 | 222,126 | 122,954 |
30 Jun 19 | 1,496,677 | 18,310 | 221,204 | 124,867 |
31 Mar 19 | 1,551,002 | -222 | 227,157 | 124,320 |
31 Dec 18 | 1,548,715 | 18,465 | 221,863 | 122,405 |
30 Sep 18 | 1,519,208 | 26,751 | 204,758 | 119,275 |
30 Jun 18 | 1,522,766 | 38,297 | 198,275 | 115,068 |
31 Mar 18 | 1,494,550 | 59,556 | 191,544 | 108,345 |
31 Dec 17 | 1,465,489 | 43,364 | 185,640 | 103,749 |
30 Sep 17 | 1,479,235 | 62,679 | 178,320 | 108,474 |
30 Jun 17 | 1,433,084 | 55,552 | 173,950 | 109,047 |
31 Mar 17 | 1,397,331 | 50,325 | 175,393 | 110,624 |
31 Dec 16 | 1,354,466 | 47,177 | 172,994 | 109,210 |
30 Sep 16 | 1,272,157 | 25,266 | 174,099 | 109,676 |
30 Jun 16 | 1,224,595 | 47,651 | 167,153 | 101,413 |
31 Mar 16 | 1,169,781 | 57,849 | 159,512 | 97,034 |
31 Dec 15 | 1,132,877 | 65,421 | 154,015 | 95,507 |
30 Sep 15 | 1,106,563 | 66,458 | 148,700 | 83,567 |
30 Jun 15 | 1,093,493 | 64,003 | 149,362 | 80,311 |
31 Mar 15 | 1,057,322 | 52,063 | 144,303 | 75,281 |
31 Dec 14 | 1,044,768 | 56,761 | 141,529 | 75,014 |
30 Sep 14 | 1,030,194 | 54,428 | 134,899 | 74,901 |
30 Jun 14 | 1,006,095 | 43,922 | 128,926 | 76,938 |
31 Mar 14 | 973,486 | 43,473 | 125,956 | 75,662 |
31 Dec 13 | 938,298 | 43,550 | 123,469 | 72,961 |
Quality Earnings: A005250 is currently unprofitable.
Growing Profit Margin: A005250 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A005250 is unprofitable, and losses have increased over the past 5 years at a rate of 50.5% per year.
Accelerating Growth: Unable to compare A005250's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A005250 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-1.3%).
Return on Equity
High ROE: A005250 has a negative Return on Equity (-6.09%), as it is currently unprofitable.